Antibodies to probe endogenous G protein-coupled receptor heteromer expression, regulation and function

Frontiers in Pharmacology

Volumn 5, Issue NOV, 2014, Pages

  Gomes, Ivone ^a   Gupta, Achla ^a   Bushlin, Ittai ^a   Devi, Lakshmi A ^a,b  

^a Department of Pharmacology and Systems Therapeutics ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin; Cannabinoid; Dimerization; G protein coupled receptor; Heteromerization; Opioid

Indexed keywords

EID: 84949116744     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00268     Document Type: Article

References (81)

1. J. H. White, A. Wise, M. J. Main, A. Green, N. J. Fraser, G. H. Disney, A. A. Barnes, P. Emson, S. M. Foord and F. H. Marshall: Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature, 396(6712), 679-682 (1998)
2. R. Kuner, G. Kohr, S. Grunewald, G. Eisenhardt, A. Bach and H. C. Kornau: Role of heteromer formation in GABAB receptor function. Science, 283(5398), 74-7 (1999)
3. J. P. Pin, L. Comps-Agrar, D. Maurel, C. Monnier, M. L. Rives, E. Trinquet, J. Kniazeff, P. Rondard and L. Prezeau: G-protein-coupled receptor oligomers: two or more for what? Lessons from mGlu and GABAB receptors. J Physiol, 587(Pt 22), 5337-44 (2009) doi:10.1113/jphysiol.2009.179978
4. L. Albizu, J. L. Moreno, J. Gonzalez-Maeso and S. C. Sealfon: Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics. CNS Neurol Disord Drug Targets, 9(5), 636-50 (2010)
5. K. Szafran, A. Faron-Gorecka, M. Kolasa, M. Kusmider, J. Solich, D. Zurawek and M. Dziedzicka-Wasylewska: Potential role of G protein-coupled receptor (GPCR) heterodimerization in neuropsychiatric disorders: a focus on depression. Pharmacol Rep, 65(6), 1498-505 (2013)
6. I. Gomes, W. Fujita, M. V. Chandrakala and L. A. Devi: Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse. Prog Mol Biol Transl Sci, 117, 207-65 (2013) doi:10.1016/B978-0-12-386931-9.00009-X
7. C. Hiller, J. Kuhhorn and P. Gmeiner: Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands. J Med Chem, 56(17), 6542-59 (2013) doi:10.1021/jm4004335
8. S. Ferre, R. Baler, M. Bouvier, M. G. Caron, L. A. Devi, T. Durroux, K. Fuxe, S. R. George, J. A. Javitch, M. J. Lohse, K. Mackie, G. Milligan, K. D. Pfleger, J. P. Pin, N. D. Volkow, M. Waldhoer, A. S. Woods and R. Franco: Building a new conceptual framework for receptor heteromers. Nat Chem Biol, 5(3), 131-4 (2009) doi:10.1038/nchembio0309-131
9. P. C. Brooks, J. M. Lin, D. L. French and J. P. Quigley: Subtractive immunization yields monoclonal antibodies that specifically inhibit metastasis. J Cell Biol, 122(6), 1351-9 (1993)
10. H. M. Sleister and A. G. Rao: Subtractive immunization: a tool for the generation of discriminatory antibodies to proteins of similar sequence. J Immunol Methods, 261(1-2), 213-20 (2002)
11. M. Yasumoto, M. Hamabashiri, J. Akiba, S. Ogasawara, Y. Naito, T. Taira, M. Nakayama, A. Daicho, F. Yamasaki, K. Shimamatsu, Y. Ishida, R. Kaji, Y. Okabe, O. Nakashima, K. Ohshima, M. Nakashima, M. Sata and H. Yano: The utility of a novel antibody in the pathological diagnosis of pancreatic acinar cell carcinoma. J Clin Pathol, 65(4), 327-32 (2012) doi:10.1136/jclinpath-2011-200442
12. U. Trefzer, N. Rietz, Y. Chen, H. Audring, G. Herberth, P. Siegel, S. Reinke, P. Koniger, S. Wu, J. Ma, Y. Liu, H. Wang, W. Sterry and Y. Guo: SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions. Arch Dermatol Res, 292(12), 583-9 (2000)
13. R. A. Salata, I. J. Malhotra, R. K. Hampson, D. F. Ayers, C. S. Tomich and F. M. Rottman: Application of an immune-tolerizing procedure to generate monoclonal antibodies specific to an alternate protein isoform of bovine growth hormone. Anal Biochem, 207(1), 142-9 (1992)
14. H. M. Sleister and A. G. Rao: Strategies to generate antibodies capable of distinguishing between proteins with >90% amino acid identity. J Immunol Methods, 252(1-2), 121-9 (2001)
15. I. Gomes, A. Gupta and L. A. Devi: G-protein-coupled heteromers: regulation in disease. Methods Enzymol, 521, 219-38 (2013) doi:10.1016/B978-0-12-391862-8.00012-0
16. A. Gupta, J. Mulder, I. Gomes, R. Rozenfeld, I. Bushlin, E. Ong, M. Lim, E. Maillet, M. Junek, C. M. Cahill, T. Harkany and L. A. Devi: Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal, 3(131), ra54 (2010) doi:10.1126/scisignal.2000807
17. I. Bushlin, A. Gupta, S. D. Stockton, Jr., L. K. Miller and L. A. Devi: Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS One, 7(12), e49789 (2012) doi:10.1371/journal.pone.0049789
18. R. Rozenfeld, A. Gupta, K. Gagnidze, M. P. Lim, I. Gomes, D. Lee-Ramos, N. Nieto and L. A. Devi: AT1R-CBR heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J, 30(12), 2350-63 (2011) doi:10.1038/emboj.2011.139
19. K. A. Berg, M. P. Rowan, A. Gupta, T. A. Sanchez, M. Silva, I. Gomes, B. A. McGuire, P. S. Portoghese, K. M. Hargreaves, L. A. Devi and W. P. Clarke: Allosteric Interactions between delta and kappa Opioid Receptors in Peripheral Sensory Neurons. Mol Pharmacol, 81(2), 264-72 (2012) doi:10.1124/mol.111.072702
20. R. B. Rothman and T. C. Westfall: Morphine allosterically modulates the binding of [3H]leucine enkephalin to a particulate fraction of rat brain. Mol Pharmacol, 21(3), 538-47 (1982)
21. W. Fujita, I. Gomes and L. A. Devi: Heteromers of mu-delta opioid receptors: new pharmacology and novel therapeutic possibilities. Br J Pharmacol (2014) doi:10.1111/bph.12663
22. L. Gendron, A. L. Lucido, F. Mennicken, D. O'Donnell, J. P. Vincent, T. Stroh and A. Beaudet: Morphine and pain-related stimuli enhance cell surface availability of somatic deltaopioid receptors in rat dorsal root ganglia. J Neurosci, 26(3), 953-62 (2006) doi:10.1523/JNEUROSCI.3598-05.2006
23. A. Morinville, C. M. Cahill, M. J. Esdaile, H. Aibak, B. Collier, B. L. Kieffer and A. Beaudet: Regulation of delta-opioid receptor trafficking via mu-opioid receptor stimulation: evidence from mu-opioid receptor knock-out mice. J Neurosci, 23(12), 4888-98 (2003)
24. C. M. Cahill, A. Morinville, M. C. Lee, J. P. Vincent, B. Collier and A. Beaudet: Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception. J Neurosci, 21(19), 7598-607 (2001)
25. H. W. Matthes, R. Maldonado, F. Simonin, O. Valverde, S. Slowe, I. Kitchen, K. Befort, A. Dierich, M. Le Meur, P. Dolle, E. Tzavara, J. Hanoune, B. P. Roques and B. L. Kieffer: Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the muopioid-receptor gene. Nature, 383(6603), 819-23 (1996) doi:10.1038/383819a0
26. H. W. Matthes, C. Smadja, O. Valverde, J. L. Vonesch, A. S. Foutz, E. Boudinot, M. Denavit-Saubie, C. Severini, L. Negri, B. P. Roques, R. Maldonado and B. L. Kieffer: Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. J Neurosci, 18(18), 7285-95 (1998)
27. Y. Zhu, M. A. King, A. G. Schuller, J. F. Nitsche, M. Reidl, R. P. Elde, E. Unterwald, G. W. Pasternak and J. E. Pintar: Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron, 24(1), 243-52 (1999)
28. P. Sanchez-Blazquez, A. Garcia-Espana and J. Garzon: Antisense oligodeoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors. J Pharmacol Exp Ther, 280(3), 1423-31 (1997)
29. S. K. Billa, Y. Xia and J. A. Moron: Disruption of morphine-conditioned place preference by a delta2-opioid receptor antagonist: study of mu-opioid and delta-opioid receptor expression at the synapse. Eur J Neurosci, 32(4), 625-31 (2010) doi:10.1111/j.1460-9568.2010.07314.x
30. T. M. Egan and R. A. North: Both mu and delta opiate receptors exist on the same neuron. Science, 214(4523), 923-4 (1981)
31. W. Zieglgansberger, E. D. French, N. Mercuri, F. Pelayo and J. T. Williams: Multiple opiate receptors on neurons of the mammalian central nervous system. In vivo and in vitro studies. Life Sci, 31(20-21), 2343-6 (1982)
32. Y. Baumhaker, Y. Wollman, M. N. Goldstein and Y. Sarne: Evidence for mu-, delta-, and kappa-opioid receptors in a human neuroblastoma cell line. Life Sci, 52(19), PL205-10 (1993)
33. S. M. Kazmi and R. K. Mishra: Comparative pharmacological properties and functional coupling of mu and delta opioid receptor sites in human neuroblastoma SH-SY5Y cells. Mol Pharmacol, 32(1), 109-18 (1987)
34. E. Palazzi, E. Ceppi, F. Guglielmetti, L. Catozzi, D. Amoroso and A. Groppetti: Biochemical evidence of functional interaction between mu- and delta-opioid receptors in SK-N BE neuroblastoma cell line. J Neurochem, 67(1), 138-44 (1996)
35. V. C. Yu, M. L. Richards and W. Sadee: A human neuroblastoma cell line expresses mu and delta opioid receptor sites. J Biol Chem, 261(3), 1065-70 (1986)
36. U. Arvidsson, M. Riedl, S. Chakrabarti, J. H. Lee, A. H. Nakano, R. J. Dado, H. H. Loh, P. Y. Law, M. W. Wessendorf and R. Elde: Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J Neurosci, 15(5 Pt 1), 3328-41 (1995)
37. P. Y. Cheng, L. Y. Liu-Chen and V. M. Pickel: Dual ultrastructural immunocytochemical labeling of mu and delta opioid receptors in the superficial layers of the rat cervical spinal cord. Brain Res, 778(2), 367-80 (1997)
38. H. Wang and V. M. Pickel: Preferential cytoplasmic localization of delta-opioid receptors in rat striatal patches: comparison with plasmalemmal mu-opioid receptors. J Neurosci, 21(9), 3242-50 (2001)
39. G. Scherrer, N. Imamachi, Y. Q. Cao, C. Contet, F. Mennicken, D. O'Donnell, B. L. Kieffer and A. I. Basbaum: Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell, 137(6), 1148-59 (2009) doi:10.1016/j.cell.2009.04.019
40. H. B. Wang, B. Zhao, Y. Q. Zhong, K. C. Li, Z. Y. Li, Q. Wang, Y. J. Lu, Z. N. Zhang, S. Q. He, H. C. Zheng, S. X. Wu, T. G. Hokfelt, L. Bao and X. Zhang: Coexpression of delta- and mu-opioid receptors in nociceptive sensory neurons. Proc Natl Acad Sci U S A, 107(29), 13117-22 (2010) doi:10.1073/pnas.1008382107
41. X. Zhang and L. Bao: Interaction and regulatory functions of mu- and delta-opioid receptors in nociceptive afferent neurons. Neurosci Bull, 28(2), 121-30 (2012) doi:10.1007/s12264-012-1206-x
42. H. Beaudry, D. Dubois and L. Gendron: Activation of spinal mu- and delta-opioid receptors potently inhibits substance P release induced by peripheral noxious stimuli. J Neurosci, 31(37), 13068-77 (2011) doi:10.1523/JNEUROSCI.1817-11.2011
43. A. Normandin, P. Luccarini, J. L. Molat, L. Gendron and R. Dallel: Spinal mu and delta opioids inhibit both thermal and mechanical pain in rats. J Neurosci, 33(28), 11703-14 (2013) doi:10.1523/JNEUROSCI.1631-13.2013
44. R. Bardoni, V. L. Tawfik, D. Wang, A. Francois, C. Solorzano, S. A. Shuster, P. Choudhury, C. Betelli, C. Cassidy, K. Smith, J. C. de Nooij, F. Mennicken, D. O'Donnell, B. L. Kieffer, C. J. Woodbury, A. I. Basbaum, A. B. MacDermott and G. Scherrer: Delta opioid receptors presynaptically regulate cutaneous mechanosensory neuron input to the spinal cord dorsal horn. Neuron, 81(6), 1312-27 (2014) doi:10.1016/j.neuron.2014.01.044
45. E. Erbs, L. Faget, G. Scherrer, A. Matifas, D. Filliol, J. L. Vonesch, M. Koch, P. Kessler, D. Hentsch, M. C. Birling, M. Koutsourakis, L. Vasseur, P. Veinante, B. L. Kieffer and D. Massotte: A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Struct Funct (2014) doi:10.1007/s00429-014-0717-9
46. W. Fujita, I. Gomes, L. S. Dove, D. Prohaska, G. McIntyre and L. A. Devi: Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol (2014) doi:10.1016/j.bcp.2014.09.015
47. S. R. George, T. Fan, Z. Xie, R. Tse, V. Tam, G. Varghese and B. F. O'Dowd: Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem, 275(34), 26128-35 (2000) doi:10.1074/jbc.M000345200
48. I. Gomes, B. A. Jordan, A. Gupta, N. Trapaidze, V. Nagy and L. A. Devi: Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. J Neurosci, 20(22), RC110 (2000)
49. I. Gomes, A. Gupta, J. Filipovska, H. H. Szeto, J. E. Pintar and L. A. Devi: A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A, 101(14), 5135-9 (2004) doi:10.1073/pnas.0307601101
50. A. Hasbi, T. Nguyen, T. Fan, R. Cheng, A. Rashid, M. Alijaniaram, M. M. Rasenick, B. F. O'Dowd and S. R. George: Trafficking of preassembled opioid mu-delta heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by agonists. Biochemistry, 46(45), 12997-3009 (2007) doi:10.1021/bi701436w
51. I. Gomes, A. P. Ijzerman, K. Ye, E. L. Maillet and L. A. Devi: G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol, 79(6), 1044-52 (2011) doi:10.1124/mol.110.070847
52. T. Fan, G. Varghese, T. Nguyen, R. Tse, B. F. O'Dowd and S. R. George: A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J Biol Chem, 280(46), 38478-88 (2005) doi:10.1074/jbc.M505644200
53. A. C. Charles, N. Mostovskaya, K. Asas, C. J. Evans, M. L. Dankovich and T. G. Hales: Coexpression of delta-opioid receptors with micro receptors in GH3 cells changes the functional response to micro agonists from inhibitory to excitatory. Mol Pharmacol, 63(1), 89-95 (2003)
54. R. Rozenfeld and L. A. Devi: Receptor heterodimerization l eads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J, 21(10), 2455-65 (2007) doi:10.1096/fj.06-7793com
55. F. M. Decaillot, R. Rozenfeld, A. Gupta and L. A. Devi: Cell surface targeting of mu delta opioid receptor heterodimers by RTP4. Proc Natl Acad Sci U S A, 105(41), 16045-50 (2008) doi:10.1073/pnas.0804106105
56. P. Y. Law, L. J. Erickson-Herbrandson, Q. Q. Zha, J. Solberg, J. Chu, A. Sarre and H. H. Loh: Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J Biol Chem, 280(12), 11152-64 (2005) doi:10.1074/jbc.M500171200
57. L. Milan-Lobo and J. L. Whistler: Heteromerization of the mu- and delta-opioid receptors produces ligand-biased antagonism and alters mu-receptor trafficking. J Pharmacol Exp Ther, 337(3), 868-75 (2011) doi:10.1124/jpet.111.179093
58. S. Q. He, Z. N. Zhang, J. S. Guan, H. R. Liu, B. Zhao, H. B. Wang, Q. Li, H. Yang, J. Luo, Z. Y. Li, Q. Wang, Y. J. Lu, L. Bao and X. Zhang: Facilitation of mu-opioid receptor activity by preventing delta-opioid receptor-mediated codegradation. Neuron, 69(1), 120-31 (2011) doi:10.1016/j.neuron.2010.12.001
59. N. Kabli, T. Nguyen, G. Balboni, B. F. O'Dowd and S. R. George: Antidepressant-like and anxiolytic-like effects following activation of the mu-delta opioid receptor heteromer in the nucleus accumbens. Mol Psychiatry, 19(9), 986-94 (2014) doi:10.1038/mp.2013.115
60. D. J. Daniels, N. R. Lenard, C. L. Etienne, P. Y. Law, S. C. Roerig and P. S. Portoghese: Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A, 102(52), 19208-13 (2005) doi:10.1073/pnas.0506627102
61. I. Gomes, W. Fujita, A. Gupta, A. S. Saldanha, A. Negri, C. E. Pinello, E. Roberts, M. Filizola, P. Hodder and L. A. Devi: Identification of a mu-delta opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A, 110(29), 12072-7 (2013) doi:10.1073/pnas.1222044110
62. A. S. Yekkirala, A. E. Kalyuzhny and P. S. Portoghese: An immunocytochemical-derived correlate for evaluating the bridging of heteromeric mu-delta opioid protomers by bivalent ligands. ACS Chem Biol, 8(7), 1412-6 (2013) doi:10.1021/cb400113d
63. J. H. Harvey, D. H. Long, P. M. England and J. L. Whistler: Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers. ACS Med Chem Lett, 3(8), 640-644 (2012) doi:10.1021/ml300083p
64. M. W. Wessendorf and J. Dooyema: Coexistence of kappa- and delta-opioid receptors in rat spinal cord axons. Neurosci Lett, 298(3), 151-4 (2001)
65. B. A. Jordan and L. A. Devi: G-protein-coupled receptor heterodimerization modulates receptor function. Nature, 399(6737), 697-700 (1999) doi:10.1038/21441
66. D. Ramsay, E. Kellett, M. McVey, S. Rees and G. Milligan: Homo- and hetero oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem J, 365(Pt 2), 429-40 (2002) doi:10.1042/BJ20020251
67. R. G. Bhushan, S. K. Sharma, Z. Xie, D. J. Daniels and P. S. Portoghese: A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. J Med Chem, 47(12), 2969-72 (2004) doi:10.1021/jm0342358
68. M. Waldhoer, J. Fong, R. M. Jones, M. M. Lunzer, S. K. Sharma, E. Kostenis, P. S. Portoghese and J. L. Whistler: A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci U S A, 102(25), 9050-5 (2005) doi:10.1073/pnas.0501112102
69. M. L. Rives, M. Rossillo, L. Y. Liu-Chen and J. A. Javitch: 6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased kappa-opioid receptor agonist that inhibits arrestin recruitment. J Biol Chem, 287(32), 27050-4 (2012) doi:10.1074/jbc.C112.387332
70. C. L. Schmid, J. M. Streicher, C. E. Groer, T. A. Munro, L. Zhou and L. M. Bohn: Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at kappa-opioid receptors in striatal neurons. J Biol Chem, 288(31), 22387-98 (2013) doi:10.1074/jbc.M113.476234
71. M. Shapira, M. Gafni and Y. Sarne: Independence of, and interactions between, cannabinoid and opioid signal transduction pathways in N18TG2 cells. Brain Res, 806(1), 26-35 (1998)
72. S. P. Welch and M. Eads: Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res, 848(1-2), 183-90 (1999)
73. F. Berrendero and R. Maldonado: Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl), 163(1), 111-7 (2002) doi:10.1007/s00213-002-1144-9
74. F. Berrendero, V. Mendizabal, P. Murtra, B. L. Kieffer and R. Maldonado: Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta and kappa-opioid receptor knockout mice. Eur J Neurosci, 18(8), 2197-202 (2003)
75. L. Uriguen, F. Berrendero, C. Ledent, R. Maldonado and J. Manzanares: Kappa- and delta-opioid receptor functional activities are increased in the caudate putamen of cannabinoid CB1 receptor knockout mice. Eur J Neurosci, 22(8), 2106-10 (2005) doi:10.1111/j.1460-9568.2005.04372.x
76. R. Rozenfeld, I. Bushlin, I. Gomes, N. Tzavaras, A. Gupta, S. Neves, L. Battini, G. L. Gusella, A. Lachmann, A. Ma'ayan, R. D. Blitzer and L. A. Devi: Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS One, 7(1), e29239 (2012) doi:10.1371/journal.pone.0029239
77. C. Rios, I. Gomes and L. A. Devi: mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol, 148(4), 387-95 (2006) doi:10.1038/sj.bjp.0706757
78. N. Lanthier, Y. Horsmans and I. A. Leclercq: The metabolic syndrome: how it may influence hepatic stellate cell activation and hepatic fibrosis. Curr Opin Clin Nutr Metab Care, 12(4), 404-11 (2009) doi:10.1097/MCO.0b013e32832c7819
79. A. Mallat and S. Lotersztajn: Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol, 294(1), G9-G12 (2008) doi:10.1152/ajpgi.00467.2007
80. S. V. Siegmund and R. F. Schwabe: Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol, 294(2), G357-62 (2008) doi:10.1152/ajpgi.00456.2007
81. F. Teixeira-Clerc, B. Julien, P. Grenard, J. Tran Van Nhieu, V. Deveaux, L. Li, V. Serriere-Lanneau, C. Ledent, A. Mallat and S. Lotersztajn: CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med, 12(6), 671-6 (2006) doi:10.1038/nm1421